In the wake of a harrowing inquest into the death of Oliver Robinson, a 34-year-old man who took his own life in November 2023, there is mounting pressure for tighter regulation of private cannabis clinics in the UK. The inquest highlighted grave concerns regarding the role of Robinson’s medicinal cannabis prescription in his deteriorating mental health and subsequent suicide, prompting his family to advocate for significant reforms in how cannabis is prescribed and monitored within the healthcare system.
The Inquest Findings
Robinson’s struggles with mental health were well documented. After years of battling depression and addiction, he sought treatment at the Priory, a private mental health facility, from 2019 to 2022. Although he initially found some relief, by the time of his death, his family believed that the medicinal cannabis he had been prescribed exacerbated his condition. An inquest revealed that Robinson’s cannabis prescription, issued by Curaleaf Clinic in May 2022, likely contributed to his death, acting as a barrier to receiving the necessary psychiatric and addiction care.
Catherine McKenna, the coroner for Manchester North, underscored the seriousness of the findings, marking this case as potentially precedent-setting. The verdict has ignited a campaign for increased oversight of private cannabis clinics, particularly concerning their prescriptions to individuals with severe mental illnesses.
Family Advocacy for Reform
Following the inquest, Robinson’s brother, Alexander, has taken the initiative to spearhead a campaign dubbed “Oliver’s Law.” This campaign seeks to impose stringent regulations on UK cannabis clinics, including a prohibition on prescribing to patients with serious mental health conditions and a requirement for closer collaboration with NHS mental health services. Alexander expressed deep concern over the implications of the current lax regulatory framework: “If things do not change, he is not going to be the last,” he stated, highlighting the urgent need for reform to protect vulnerable patients.
The legalisation of medicinal cannabis in the UK in 2018 was a pivotal moment for many seeking alternative treatments. However, the lack of robust clinical guidelines has led to widespread prescribing of unlicensed cannabis products. According to the Care Quality Commission (CQC), the vast majority of cannabis prescriptions in private clinics fall into this category, raising questions about their safety and efficacy, particularly for those with complex psychiatric histories.
The Efficacy of Medicinal Cannabis
Dr Pavan Chahl, an expert psychiatrist who testified at the inquest, asserted that there is insufficient evidence to support the use of cannabis for treating depression. He pointed out that current guidelines recommend against prescribing it to individuals with a history of severe psychiatric disorders due to the potential for worsening symptoms. Despite this, the market for private cannabis prescriptions has skyrocketed, with over 659,000 unlicensed products prescribed in 2024 alone—more than double the amount from the previous year.
Robinson’s experience reflects a troubling reality for many seeking relief through cannabis. Initially, he found some temporary solace in the drug, but as his case progressed, it became clear that the substance was not addressing the underlying issues. His family’s accounts paint a devastating picture of a man who spiralled into violence and isolation, exacerbated by his cannabis use.
The Response from Cannabis Clinics
In the wake of the inquest, Curaleaf Clinic expressed condolences to Robinson’s family and stated its commitment to clinical governance and patient safety. The clinic highlighted that all prescribing decisions are made by a multidisciplinary team and adhere to an evidence-based practice. They have pledged to engage with any regulatory reviews aimed at enhancing patient safety across the sector.
However, the CQC’s rating of “good” for Curaleaf raises questions about the adequacy of existing oversight mechanisms. The coroner’s report identified several failings in Robinson’s care, including the reliance on outdated medical records and insufficient communication between private and NHS care providers.
Why it Matters
The tragic case of Oliver Robinson underscores a critical need for reform in the regulation of private cannabis clinics in the UK. As the landscape of medicinal cannabis continues to evolve, the health and safety of patients must remain paramount. The push for stricter regulations, including the prohibition of prescriptions for those with severe mental health issues, is essential to prevent further tragedies. This case serves as a stark reminder of the potential dangers of unchecked medical practices and the imperative for a healthcare system that prioritises comprehensive, evidence-based care for all patients.
